FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103262460> ?p ?o ?g. }

• W2103262460 abstract "Background Souvenaid is a dietary supplement with a patented composition (Fortasyn Connect™)which is intended to be used by people with Alzheimer's disease (AD). It has been designed to support the formation and function of synapses in the brain, which are thought to be strongly correlated with cognitive function. If effective, it might improve symptoms of Alzheimer's disease and also prevent the progression from prodromal Alzheimer's disease to dementia. We sought in this review to examine the evidence for this proposition. Objectives To assess the effects of Souvenaid on incidence of dementia, cognition, functional performance, and safety in people with Alzheimer's disease. Search methods We searched ALOIS, i.e. the specialised register of the Cochrane Dementia and Cognitive Improvement Group, MEDLINE (Ovid SP), Embase (Ovid SP), PsycINFO (Ovid SP), Web of Science (ISI Web of Science), Cinahl (EBSCOhost), Lilacs (BIREME), and clinical trials registries up to 24 June 2020. We also reviewed citations of reference lists of landmark papers, reviews, and included studies for additional studies and assessed their suitability for inclusion in the review. Selection criteria We included randomised, placebo‐controlled trials which evaluated Souvenaid in people diagnosed with mild cognitive impairment (MCI) due to AD (also termed prodromal AD) or with dementia due to AD, and with a treatment duration of at least 16 weeks. Data collection and analysis Our primary outcome measures were incidence of dementia, global and specific cognitive function, functional performance, combined cognitive‐functional outcomes and adverse events. We selected studies, extracted data, assessed the quality of trials and intended to conduct meta‐analyses according to the Cochrane Handbook for Systematic Reviews of Interventions. We rated the quality of the evidence using the GRADE approach. We present all outcomes grouped by stage of AD. Main results We included three randomised, placebo‐controlled trials investigating Souvenaid in 1097 community‐dwelling participants with Alzheimer's disease. One study each included participants with prodromal AD, mild AD dementia and mild‐to‐moderate AD dementia. We rated the risks of bias of all trials as low. One study (in prodromal AD) was funded by European grants. The other two studies were funded by the manufacturer of Souvenaid. One trial investigated the incidence of dementia in people with prodromal AD at baseline, and found little to no difference between the Souvenaid group and the placebo group after 24 months (RR 1.09, 95% CI 0.82 to 1.43; 1 trial, 311 participants; moderate quality of evidence). In prodromal AD, and in mild and mild‐to‐moderate Alzheimer's disease dementia, Souvenaid probably results in little or no difference in global or specific cognitive functions (moderate quality of evidence). Everyday function, or the ability to perform activities of daily living, were measured in mild and mild‐to‐moderate AD dementia. Neither study found evidence of a difference between the groups after 24 weeks of treatment (moderate quality of evidence). Two studies investigated combined cognitive‐functional outcomes with the Clinical Dementia Rating Sum of Boxes and observed conflicting results. Souvenaid probably results in slight improvement, which is below estimates of meaningful change, in participants with prodromal Alzheimer's disease after 24 months (moderate quality of evidence), but probably has little to no effect in mild‐to‐moderate Alzheimer's disease dementia after 24 weeks (moderate quality of evidence). Adverse effects observed were low in all trials, and the available data were insufficient to determine any connection with Souvenaid. Authors' conclusions Two years of treatment with Souvenaid probably does not reduce the risk of progression to dementia in people with prodromal AD. There is no convincing evidence that Souvenaid affects other outcomes important to people with AD in the prodromal stage or mild‐to‐moderate stages of dementia. Conflicting evidence on combined cognitive‐functional outcomes in prodromal AD and mild AD dementia warrants further investigation. Adverse effects of Souvenaid seem to be uncommon, but the evidence synthesised in this review does not permit us to make a definitive statement on the long‐term tolerability of Souvenaid. The effects of Souvenaid in more severe AD dementia or in people with AD at risk of nutritional deficiencies remain unclear." @default.
• W2103262460 created "2016-06-24" @default.
• W2103262460 creator A5016788997 @default.
• W2103262460 creator A5033409292 @default.
• W2103262460 creator A5068177705 @default.
• W2103262460 creator A5069090373 @default.
• W2103262460 creator A5087041541 @default.
• W2103262460 date "2020-12-15" @default.
• W2103262460 modified "2023-10-17" @default.
• W2103262460 title "Souvenaid for Alzheimer's disease" @default.
• W2103262460 cites W1164896577 @default.
• W2103262460 cites W1507743940 @default.
• W2103262460 cites W1509595387 @default.
• W2103262460 cites W1547180086 @default.
• W2103262460 cites W1752793417 @default.
• W2103262460 cites W1847168837 @default.
• W2103262460 cites W1919272385 @default.
• W2103262460 cites W1953027527 @default.
• W2103262460 cites W1965529356 @default.
• W2103262460 cites W1968911552 @default.
• W2103262460 cites W1974806875 @default.
• W2103262460 cites W1989765905 @default.
• W2103262460 cites W1993317889 @default.
• W2103262460 cites W1996776294 @default.
• W2103262460 cites W2008854521 @default.
• W2103262460 cites W2010149513 @default.
• W2103262460 cites W2015933608 @default.
• W2103262460 cites W2032389768 @default.
• W2103262460 cites W2044730241 @default.
• W2103262460 cites W2057843174 @default.
• W2103262460 cites W2058161128 @default.
• W2103262460 cites W2058803950 @default.
• W2103262460 cites W2065338300 @default.
• W2103262460 cites W2078637572 @default.
• W2103262460 cites W2096321911 @default.
• W2103262460 cites W2099716808 @default.
• W2103262460 cites W2102343148 @default.
• W2103262460 cites W2103262460 @default.
• W2103262460 cites W2106931873 @default.
• W2103262460 cites W2109031511 @default.
• W2103262460 cites W2111200377 @default.
• W2103262460 cites W2115017507 @default.
• W2103262460 cites W2116709840 @default.
• W2103262460 cites W2121341819 @default.
• W2103262460 cites W2128047032 @default.
• W2103262460 cites W2129497119 @default.
• W2103262460 cites W2130241641 @default.
• W2103262460 cites W2132842417 @default.
• W2103262460 cites W2135232828 @default.
• W2103262460 cites W2144702521 @default.
• W2103262460 cites W2148080316 @default.
• W2103262460 cites W2148399486 @default.
• W2103262460 cites W2151027049 @default.
• W2103262460 cites W2152768399 @default.
• W2103262460 cites W2157520785 @default.
• W2103262460 cites W2157823046 @default.
• W2103262460 cites W2159122349 @default.
• W2103262460 cites W2160475077 @default.
• W2103262460 cites W2167311298 @default.
• W2103262460 cites W2193764494 @default.
• W2103262460 cites W2196216222 @default.
• W2103262460 cites W2263572070 @default.
• W2103262460 cites W2309442902 @default.
• W2103262460 cites W2315809371 @default.
• W2103262460 cites W2576440140 @default.
• W2103262460 cites W2582524520 @default.
• W2103262460 cites W2588681363 @default.
• W2103262460 cites W2766767762 @default.
• W2103262460 cites W2965878453 @default.
• W2103262460 cites W2972823183 @default.
• W2103262460 cites W2976847114 @default.
• W2103262460 cites W4247372942 @default.
• W2103262460 cites W4247759744 @default.
• W2103262460 cites W4249317137 @default.
• W2103262460 cites W4251986800 @default.
• W2103262460 cites W4378711534 @default.
• W2103262460 doi "https://doi.org/10.1002/14651858.cd011679.pub2" @default.
• W2103262460 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8094446" @default.
• W2103262460 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33320335" @default.
• W2103262460 hasPublicationYear "2020" @default.
• W2103262460 type Work @default.
• W2103262460 sameAs 2103262460 @default.
• W2103262460 citedByCount "5" @default.
• W2103262460 countsByYear W21032624602020 @default.
• W2103262460 countsByYear W21032624602023 @default.
• W2103262460 crossrefType "journal-article" @default.
• W2103262460 hasAuthorship W2103262460A5016788997 @default.
• W2103262460 hasAuthorship W2103262460A5033409292 @default.
• W2103262460 hasAuthorship W2103262460A5068177705 @default.
• W2103262460 hasAuthorship W2103262460A5069090373 @default.
• W2103262460 hasAuthorship W2103262460A5087041541 @default.
• W2103262460 hasBestOaLocation W21032624602 @default.
• W2103262460 hasConcept C118552586 @default.
• W2103262460 hasConcept C126322002 @default.
• W2103262460 hasConcept C142724271 @default.
• W2103262460 hasConcept C15744967 @default.
• W2103262460 hasConcept C169900460 @default.
• W2103262460 hasConcept C17744445 @default.
• W2103262460 hasConcept C199539241 @default.
• W2103262460 hasConcept C204787440 @default.

• next